Indication
Mixed Mesodermal (Mullerian) Tumor
1 clinical trial
2 drugs
Clinical trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Drug
LurbinectedinDrug
T-VEC1 clinical trial
2 drugs